Rigel Pharmaceuticals Inc.
09/19/2024 | Press release | Distributed by Public on 09/19/2024 14:02
Management Change/Compensation Form 8 K
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On September 16, 2024, Dr. Brian Kotzin notified Rigel Pharmaceuticals, Inc. ("Rigel") of his decision to resign as a member of the Board of Directors of Rigel (the "Board") and from the committees on which he serves, effective September 16, 2024. At the time of Dr. Kotzin's resignation, he was an independent director and member of the Corporate Governance, Healthcare Compliance Oversight, and Nominating Committee of the Board, and chair of the Scientific and Clinical Trial Advisory Committee of the Board. Dr. Kotzin's decision to resign was not a result of any disagreement with Rigel on any matter relating to the Rigel's operations, policies or practices.